ArticleFrontiers in pediatrics2026
Case Report: Pediatric immune-mediated necrotizing myopathies mimicking inherited muscle disorders: clinical, paraclinical, and genetic insights from two cases.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Immune-mediated necrotizing myopathies (IMNMs) are a group of rare acquired myopathies. We describe two pediatric cases presenting with early-onset proximal and axial muscle weakness, rhabdomyolysis, and progressive evolution mimicking limb-girdle muscular dystrophy. Methods: This retrospective case series is based on a review of the medical records of two pediatric IMNM patients with symptom onset at 2 (P1) and 16 (P2) years of age and diagnoses at 5 and 17 years, respectively. Both patients underwent clinical assessment, muscle biopsy, whole-body muscle MRI, a testing for myositis-specific and myositis-associated autoantibodies, whole-exome sequencing, and Results: Both patients presented with an early onset of severe muscle weakness, compatible with the clinical suspicion of limb-girdle muscular dystrophy. P1's serological screening was positive for anti-signal recognition particle antibodies, and muscle biopsy revealed a myopathological pattern compatible with IMNM. Treatment with corticosteroids, intravenous immunoglobulin (IVIG), and rituximab resulted in partial amelioration of muscle strength. P2's screening for myositis autoantibodies was negative. Muscle biopsy showed a dystrophic pattern with the absence of dysferlin. Whole-exome sequencing did not identify any compatible variants explaining the muscle phenotype in both patients. P2 was treated with corticosteroids, IVIG, and rituximab, resulting in normalization of muscle weakness and creatine kinase (CK) levels. Conclusion: IMNM should be considered in pediatric patients with clinical and paraclinical suspicion of inherited muscular dystrophy. Serological testing is crucial for identifying seropositive cases. In the presence of seronegative or more complex cases, a global paraclinical and genetic analysis is essential to avoid misdiagnosis and initiate long-term immunosuppressive therapy, including corticosteroids, IVIG, and rituximab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.